Literature database

The use of intravenous immune globulin in multiple myeloma.

The use of intravenous immune globulin in multiple myeloma.

Chapel HM, Lee M.
Clin Exp Immunol. 1994 Jul;97 Suppl 1:21-4.


Department of Immunology, John Radcliffe Hospital, Oxford, UK.

Patients with multiple myeloma suffer from serious bacterial infections throughout the course of the disease. This is probably associated with reduced polyclonal immunoglobulin synthesis. Prophylactic intravenous immune globulin (IVIG) reduces the incidence and recurrence of these infections in the stable phase of the disease. Infections at times of induction chemotherapy and/or relapse have a wider range of causative organisms. Such susceptibility may be associated with abnormal phagocytic function following chemotherapy.

Publication Types:
  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

PMID: 8033429 [PubMed - indexed for MEDLINE]